Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.
Agenda

Overview | Strategy

Mid-term Growth Prospects

FY 2020 Results | FY 2021 Guidance

Appendix
A leading partner of the biopharma industry

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

The United Nations’ sustainability goal ‘Good Health and Well-Being’ is thus an integral part of our core business.
Sartorius Stedim Biotech at a glance

- **€ ~1.9bn**
  Sales revenue 2020

- **~16.5%**
  Sales CAGR\(^1\) 2015-2020

- **~31.7%**
  EBITDA margin\(^2\) 2020

- **>20**
  countries, headquartered in Aubagne, France

- **> 7,500**
  Employees

**Four strong pillars drive above-average growth**

- **Pharma market**
  CAGR 4-7%

- **Biopharma market**
  CAGR ~10%

- **Single-use penetration**
  Double-digit growth

- **Market share gains**
  Esp. in North America

---

\(^1\) In constant currencies  \(^2\) Excluding extraordinary items
Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships
Generating revenue throughout the lifecycle of a biopharma drug

- Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability
- Engineering support with excellent application knowhow and understanding of the entire bio-production process
- Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval
Integrated services and technologies for all types of biopharmaceuticals

- ~95% of revenue generated with bio/pharma customers
- Antibodies are most relevant; strong position in vaccines as well
- SSB provides solutions for the development and production of all biotechnologically derived drugs and cell derivatives
- These also include new modalities such as cell and gene therapies and viral vectors
Attractive market environment with strong growth opportunities

- **Favorable demographics**
  - 9bn people by 2050; >2bn 60 yrs or older

- **Rise of biosimilars**
  - ~30% CAGR for biosimilar sales 2020–2025

- **Strong R&D pipeline; advances in gene and cell therapy**
  - >40% share of biologics in pharma R&D pipeline

- **~10% CAGR for biopharma market 2020–2025**
Sales revenue more than doubled over the last 5 years

Sales CAGR  ~+15.5%
EBITDA¹ margin  +10.8pp

~€477m  20.9  2011
 21.5  2012
 23.0  2013
 23.5  2014
 26.2  2015
 27.5  2016
 27.3  2017
 28.2  2018
 29.3  2019
 31.7  2020

~€1.9bn

Sales growth and CAGR in constant currencies ¹ Excluding extraordinary items
M&A strategy – adding innovation, enhancing focus

**Acquisition criteria**

- **Portfolio**: Complementary products or technologies
- **Market position**: Either among the Top 3 or unique selling point
- **Integration**: Management capacity; cultural fit
- **Price**: Fair valuation; reach Sartorius’ profitability level in 2-3 years

---

1. Acquired from Danaher

---

2015 - Bio Outsource
2016 - Cellca
2017 - kSep
2018 - Umetrics
2019 - Biological Industries
2020 - Life Science assets
2021 - BIA Separations

---

Cellsca
Outsource
kSep
Umetrics
BIA
WaterSep

---

1 Acquired from Danaher
Recent acquisitions strengthen portfolio...

**Acquisition of selected life science assets from Danaher**

- ~$275m Purchase price
- ~$100m Sales revenue in 2019
- +100 Employees
- May 2020 Date of consolidation

- Portfolio of upstream and downstream technologies

**Acquisition of BIA Separations**

- €360mn Purchase price¹
- ~€25m Sales revenue in 2020e
- +120 Employees
- Nov. 2020 Date of consolidation

- Technology for purification in advanced therapy processes
...especially in downstream

### Acquisition of WaterSep BioSeparations

<table>
<thead>
<tr>
<th>Sales revenue in 2020e</th>
<th>Employees</th>
<th>Date of consolidation</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$2.5m</td>
<td>+15</td>
<td>Dec. 2020</td>
</tr>
</tbody>
</table>

- Innovative hollow fiber crossflow filtration units
- Purchase price $27mn plus earn-out

### Agreement to acquire chromatography process equipment division from Novasep

<table>
<thead>
<tr>
<th>Sales revenue in 2020e</th>
<th>Employees</th>
<th>Closing expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>~€37m</td>
<td>+100</td>
<td>H1 2021</td>
</tr>
</tbody>
</table>

- Resin-based batch and intensified chromatography systems
- Purchase price not disclosed
Acquisition of selected Danaher life science assets strengthens chromatography portfolio

- Assets include chromatography systems, columns and resins; indispensable for the purification of biologics
- Well-established technologies and innovative solutions in the high-growth areas of single-use and intensified purification
- Complement existing membrane-based solutions enabling SSB to support purification strategies at all scales
Recent acquisitions also strengthen offering in other key technologies

- Extensive portfolio of cell culture media with focus on advanced therapies (e.g. cell and gene therapies)
- Gives Sartorius Stedim Biotech own production and development capabilities
- Access to customers in an increasingly important and fast-growing market

Tangential flow filtration systems
- Closing last gaps in TFF portfolio
- Highly competitive product portfolio

Microcarriers
- To support growth of adherent cell cultures

Cell culture media

---

1 Part of the selected life since assets acquired from Danaher in Q1 2020; 2 Product portfolio of Biological Industries acquired in Q4 2019
BIA Separations - Bioprocessing innovator, addressing bottlenecks in advanced therapies

- Ajdovščina, Slovenia
- ~120 employees
- Quadrupling production capacity till end 2021

**Portfolio**
- Pre-packed monolithic columns optimized for purification in advanced therapy processes (e.g. viruses, plasmids, exosomes)
- Provides significantly higher yield by avoiding shearing effects which occur in traditional purification processes, e.g. in chromatography

**Positioning**
- Monoliths already used in production of first commercialized advanced therapeutics
- Strong presence in (pre-) clinical projects
WaterSep BioSeparations – Further broadening our filtration portfolio

Marlborough, USA
~15 employees
R&D and production of membranes and cartridges

Portfolio
- Hollow-fiber membrane devices and pre-sterilized assemblies for crossflow filtration applications in upstream and downstream
- Addresses customer needs for cost- and time-saving solutions

Strategic fit
- Complements offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing

Hollow fiber cartridges
# Competitive portfolio across our relevant end-markets

<table>
<thead>
<tr>
<th></th>
<th>SSB</th>
<th>Merck</th>
<th>Millipore</th>
<th>Pall</th>
<th>Danaher</th>
<th>Cytiva</th>
<th>Thermo Fisher</th>
<th>Top 3 Players</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filtration</td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td><img src="image" alt="Filtration" /></td>
<td>1. Merck</td>
</tr>
<tr>
<td>Fluid Management</td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td><img src="image" alt="Fluid Management" /></td>
<td>1. Sartorius Stedim Biotech 2. Thermo Fisher 3. Merck</td>
</tr>
<tr>
<td>Fermentation</td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td><img src="image" alt="Fermentation" /></td>
<td>1. Sartorius Stedim Biotech 2. Thermo Fisher 3. Danaher</td>
</tr>
<tr>
<td>Purification</td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td><img src="image" alt="Purification" /></td>
<td>1. Danaher</td>
</tr>
<tr>
<td>Cell Culture Media</td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td><img src="image" alt="Cell Culture Media" /></td>
<td>1. Thermo Fisher 2. Merck</td>
</tr>
</tbody>
</table>

1 Formerly GE Biopharma

Pie charts indicate completeness of product offering.
Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars

<table>
<thead>
<tr>
<th></th>
<th>Reference</th>
<th>Single-use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Construction cost</td>
<td>-25-35%</td>
<td>-30-50%</td>
</tr>
<tr>
<td>Time-to-market</td>
<td>-30-50%</td>
<td>-55-65%</td>
</tr>
<tr>
<td>Energy cost</td>
<td>-55-65%</td>
<td>-65-75%</td>
</tr>
<tr>
<td>Water cost</td>
<td>-65-75%</td>
<td></td>
</tr>
</tbody>
</table>
Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of our clients

<table>
<thead>
<tr>
<th>Clinical Phase I</th>
<th>Clinical Phase II</th>
<th>Clinical Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability that candidate advances to next stage</td>
<td>~60%</td>
<td>~30%</td>
</tr>
<tr>
<td>Probability of approval</td>
<td>~10%</td>
<td>~15%</td>
</tr>
</tbody>
</table>

Data based on: Wong et al. (2018): Estimation of clinical trial success rates and related parameters
Limited dependence on individual accounts

- More than half of 2020 SSB sales were generated with the Top 50 customers
- No individual customer accounts for more than 5% of BPS sales revenue

Long-term business relationships with leading global (bio-) pharma companies

Sales to Top 50 customers in 2020, € in millions

- Top 10: ~28%
- 11 to 20: ~40%
- 21 to 30: ~48%
- 31 to 40: ~53%
- 41 to 50: ~57%

Cumulative share

Cumulative share

GSK, Novartis, Boehringer Ingelheim, Lonza, Sanofi, Roche, Pfizer, Amgen, Bayer HealthCare Pharmaceuticals, MSD
Our products are widely used in the development and production of biologics against COVID-19

180+ companies developing corona vaccines
The majority work with SSB products

Pandemic effects in 2020

Pandemic-related net effect of a good ~12pp on sales revenue and close to ~19pp on order intake growth; consisting of investments in vaccine and therapeutic research and manufacturing, also inventory build-up
Agenda

Overview | Strategy

Mid-term Growth Prospects

FY 2020 Results | FY 2021 Guidance

Appendix
2025 ambition – increased baseline and organic growth

- Initial 2025 group sales revenue targets were based on an estimated 2020 group revenue of €1.5 to 1.6bn, based on the mid-term guidance of 2012.
- Actual 2020 Group revenue was approx. €1.9bn.
- New mid-term target reflects both the elevated baseline and future growth prospects.
- Continued strategy is to achieve the targets primarily through organic growth; acquisition to contribute underproportionally.
- The increase in the profitability outlook is due to economies of scale and also reflects the assumption of acquisitions to be initially dilutive.

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales revenue</strong></td>
</tr>
<tr>
<td>€4bn</td>
</tr>
<tr>
<td>previously ~€2.8bn</td>
</tr>
<tr>
<td><strong>EBITDA margin</strong></td>
</tr>
<tr>
<td>~33%</td>
</tr>
<tr>
<td>previously ~30%</td>
</tr>
</tbody>
</table>

2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items.
U.S. remains most important market; China with highest growth rates

Biologics market growth forecast

<table>
<thead>
<tr>
<th>Region</th>
<th>2020</th>
<th>2024</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>~€250bn</td>
<td>~€365bn</td>
<td>~+9% U.S.</td>
</tr>
<tr>
<td>Europe</td>
<td>~46</td>
<td>~58</td>
<td>~+6% Europe</td>
</tr>
<tr>
<td>China</td>
<td>~38</td>
<td>~67</td>
<td>~+15% China</td>
</tr>
<tr>
<td>ROW</td>
<td>~47</td>
<td>~72</td>
<td></td>
</tr>
</tbody>
</table>

U.S. remains most important market; China with highest growth rates.
Dynamic increase in new biopharma companies in China in the past years

- Huge market potential due to population size and growing average demand
- Biopharma market development priority for China
- Currently a CDMO/biosimilar-driven market; with an increasing number of originators across all biopharma modalities
- Sartorius with long-standing local presence (production in Shanghai and Beijing); further expansion planned

### China

- 26 before 1990
- 50 1990-2000
- 79 2000-2010
- 141 2010-2020

### U.S.

- 111 before 1990
- 179 1990-2000
- 269 2000-2010
- 228 2010-2020

### Europe

- 31 before 1990
- 55 1990-2000
- 69 2000-2010
- 39 2010-2020
Regional balance better reflecting end-markets

Sales by region 2011:
- Asia | Pacific: 20% (~+16%)
- Americas: 27% (~+18%)
- EMEA: 53% (~+11%)

Sales by region 2020:
- Asia | Pacific: 25% (~+16%)
- Americas: 35% (~+18%)
- EMEA: 40% (~+11%)

Global biopharma market 2019:
- Asia | Pacific: 28% (50%)
- Americas: 22% (50%)
- EMEA: 50% (28%)

CAGR for continued operations, in constant currencies

Mid-term Growth Prospects
Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market
€ in billions

<table>
<thead>
<tr>
<th>Year</th>
<th>Biosimilars</th>
<th>Other biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>~14.5</td>
<td>~235.5</td>
</tr>
<tr>
<td>2024</td>
<td>~41.5</td>
<td>~323.5</td>
</tr>
</tbody>
</table>

Growing number of biosimilar approvals
E.U. and U.S.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>7</td>
<td>22</td>
<td>20</td>
<td>15</td>
<td>16</td>
</tr>
</tbody>
</table>
High innovation dynamics in Biopharma

- Development of new drugs and vaccines must be accelerated, e.g. through more automation
- Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars
- New tools and methods required e.g. for novel cell and gene therapies
- Future drug manufacturing is more automated, intensified and scalable
Analytical technologies to improve process economics and safety

- Bioprocess sensors, analyzers and software
- Collect, monitor and control quality-critical parameters
- Analyze data to obtain a better process understanding
- Use knowledge for process development, optimization and automation
- Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality
- Intention to upgrade Umetrics software suite with advanced analytics technologies such as AI and machine learning
- Data analytics just at the beginning in biomanufacturing with high potential
Agenda

Overview | Strategy

Mid-term Growth Prospects

FY 2020 Results | FY 2021 Guidance

Appendix
## Exceptionally strong growth in 2020

### Sartorius Stedim Biotech Group

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>▲ in %</th>
<th>▲ in % cc(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>1,440.6</td>
<td>1,910.1</td>
<td>+32.6</td>
<td>+34.6</td>
</tr>
<tr>
<td>Order intake</td>
<td>1,543.5</td>
<td>2,381.0</td>
<td>+54.3</td>
<td>+56.7</td>
</tr>
<tr>
<td>Underlying EBITDA(^2)</td>
<td>421.5</td>
<td>604.7</td>
<td>+43.5</td>
<td></td>
</tr>
<tr>
<td>Underlying EBITDA(^2) margin in %</td>
<td>29.3</td>
<td>31.7</td>
<td>+2.4pp</td>
<td></td>
</tr>
<tr>
<td>Underlying EPS(^3) in €</td>
<td>2.85</td>
<td>4.16</td>
<td>+45.9</td>
<td></td>
</tr>
</tbody>
</table>

1 Constant currencies  
2 Underlying = excluding extraordinary items  
3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

- Strong organic development; pandemic-driven effects a good 12pp (majority of that from demand related to coronavirus vaccines and therapeutics), acquisitions accounted for close to 6pp of growth
- Pandemic-related effects on order intake growth close to 19pp
- Underl. EBITDA margin up with economies of scale, lower costs due to pandemic; slight FX dilution, M&A with neutral effect

---

\(^1\) Constant currencies  
\(^2\) Underlying = excluding extraordinary items  
\(^3\) Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
Double-digit sales growth in all geographies

- Especially EMEA and Americas benefited from additional demand in connection with the development and manufacture of coronavirus vaccines and Covid-19 therapeutics
- Asia|Pacific with the highest momentum, fueled by larger project business orders in H1

Acc. to customers’ location; growth in constant currencies
# Operating cash flow rises significantly

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>2019</th>
<th>2020</th>
<th>▲ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying EBITDA</td>
<td>421.5</td>
<td>604.7</td>
<td>+43.5</td>
</tr>
<tr>
<td>Extraordinary items</td>
<td>-16.8</td>
<td>-32.0</td>
<td>n.m.</td>
</tr>
<tr>
<td>Financial result</td>
<td>-14.4</td>
<td>10.8</td>
<td>n.m.</td>
</tr>
<tr>
<td>Underlying net profit&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>263.0</td>
<td>383.8</td>
<td>+45.9</td>
</tr>
<tr>
<td>Reported net profit&lt;sup&gt;2&lt;/sup&gt;</td>
<td>234.5</td>
<td>357.8</td>
<td>+52.6</td>
</tr>
<tr>
<td>Operating cash flow</td>
<td>310.1</td>
<td>416.9</td>
<td>+34.4</td>
</tr>
<tr>
<td>Investing cash flow&lt;sup&gt;3&lt;/sup&gt;</td>
<td>-184.4</td>
<td>-621.1</td>
<td>n.m.</td>
</tr>
<tr>
<td>CAPEX ratio (in %)</td>
<td>9.4</td>
<td>8.3</td>
<td>-1.1pp</td>
</tr>
</tbody>
</table>

- Net operating cash flow mostly driven by higher earnings and factoring program (~€76m)
- Extraordinary items influenced primarily by M&A
- Financial result includes the valuation effect related to the earn-out from the acquisition of BIA Separations
- Tax rate at 25.3%; excluding earn-out effect tax rate would be 27.1%
- Investing cash flow driven by acquisitions

---

<sup>1</sup> Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and normalized tax rate
<sup>2</sup> After non-controlling interest
<sup>3</sup> Net cash flow from investing activities and acquisitions

---

2019 numbers partly adjusted due to final PPA of BI
**Key Financial Indicators**

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech</th>
<th>Dec. 31, 2019</th>
<th>Dec. 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity ratio in %</td>
<td>64.4</td>
<td>48.3</td>
</tr>
<tr>
<td>Net debt in millions of €</td>
<td>110.4</td>
<td>527.0</td>
</tr>
<tr>
<td>Net debt</td>
<td>underlying EBITDA(^1)</td>
<td>0.3</td>
</tr>
</tbody>
</table>

- Equity ratio influenced by increase in balance sheet sum due to the recent acquisitions and higher cash position

---

\(^1\) Includes underlying pro forma EBITDA of acquisitions completed in 2020
Strong outlook for 2021, uncertainties remain high

<table>
<thead>
<tr>
<th>FY 2021 Guidance¹</th>
<th>Sales revenue growth</th>
<th>Underlying EBITDA margin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2021</td>
</tr>
<tr>
<td>Sartorius Stedim Biotech</td>
<td>34.6%</td>
<td>~ 20-26%</td>
</tr>
<tr>
<td>- growth by acquisitions</td>
<td>close to 6pp</td>
<td>good 12pp</td>
</tr>
</tbody>
</table>

- Growth rates expected to be significantly pronounced in H1 due to last year’s acquisition and strong order book
- CAPEX ratio ~15% (FY 2020: 8.3%); increase due to acceleration and extension of capacity expansions across the entire production network, especially in Germany, Puerto Rico and China
- Net debt to underlying EBITDA is projected at around 0.75 (2020: 0.8)

¹ In constant currencies
Agenda

Overview | Strategy

Mid-term Growth Prospects

FY 2020 Results | FY 2021 Guidance

Appendix
To Sartorius Stedim Biotech, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

SRI Presentation

Please click below for further financial information:

- Annual Report 2020
- Earnings Release 9M 2020
- Half-Year Report H1 2020
- Earnings Release Q1 2020
Sartorius Stedim Biotech shares – an attractive investment

- Biopharma market fueled by long-term growth drivers
- Leading market positions in key technologies and high brand awareness
- Global presence with strong base in growth regions

- High entry barriers, low price-sensitivity and consolidated competitive landscape
- Diversified revenue base and high share of recurring revenues provide low volatility
- Proven growth track record: Sales CAGR of ~17% over the last five years
Share price performance

ISIN: FR0013154002
Ticker: DIM
Number of share: 92,180,190

Indices:
- SBF 120
- CAC Next 20
- CAC Large 60
- CAC All-Tradable
- CAC All Shares
- CAC Healthcare
- MSCI Europe
- STOXX Europe 600

Market cap.: €37.9bn (as of February 16, 2021)
A sampling of the product portfolio

Filtration

Purification

Fermentation

Fluid management
On track to meet 2020 targets

Strategic initiatives

Regional
- Further grow sales force effectiveness ✔
- Gain share in North America ✔
- Leverage market growth in Asia ✔

Portfolio
- Alliances and acquisitions ✔
- Own product development ✔

Operations
- Continued capacity expansion ✔
- Drive digitalization and roll-out of efficient IT systems ✔

2020 targets

- ~€1.5-1.6bn
  Sales revenue

- ~4/5
  Organic

- ~1/5
  Acquisitions

- ~29-30%
  EBITDA margin

2025 targets are based on 2017 currency exchange rates; non-organic revenue growth is accounted for companies acquired from 2018 and onwards; EBITDA excluding extraordinary items.
Financial calendar and contacts

- **March 26, 2021**
  Annual Shareholders’ Meeting | Göttingen

- **April 21, 2021**
  Publication First-Quarter Results 2021 | Göttingen

Petra Kirchhoff
Head of Corporate Communications & IR
Phone: +49.551.308.1686
E-mail: petra.kirchhoff@sartorius.com

Ben Orzelek
Head of Investor Relations
Phone: +49.551.308.1668
E-mail: ben.orzelek@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany